drugset
drugset / Trial / NCT00397059

Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

NCT00397059 ↗

Phase 4 Completed 16 enrolled University of Southern Denmark H. Lundbeck A/S · collab
RandomizedCrossoverDouble-blindTreatment

Summary

To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg —

Indications

No indication recorded.